ST Bailing Co., Ltd.

Announcement on Approval of First Traditional Chinese Medicine Class II Protected Variety

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. announces that its Compound Artemisia Scoparia Spray has been approved as the first Traditional Chinese Medicine Class II Protected Variety by the National Medical Products Administration. This approval, valid for seven years, is expected to enhance market competitiveness and intellectual property advantages for the company's leading product.

Legal Opinion on the 2025 Annual General Meeting of Guizhou BaiLing Pharmaceutical Co., Ltd.

This legal opinion reviews the convening and holding procedures, attendee qualifications, and voting procedures and results of Guizhou BaiLing Pharmaceutical Co., Ltd.'s 2025 Annual General Meeting. All reviewed aspects comply with relevant laws, regulations, and the company's articles of association and meeting rules. The resolutions passed are deemed legal and valid.

Announcement on the Resolution of the 2025 Annual Shareholders' Meeting

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. announces the resolutions of its 2025 Annual Shareholders' Meeting. The meeting was held on May 18, 2026, with 530 shareholders attending in person or online, representing 32.5241% of the total voting shares. Key resolutions passed include the Board of Directors' work report, the annual report, the appointment of auditors, the profit distribution plan, and the remuneration of directors and senior management. All resolutions were approved.

Announcement on the Remuneration Plan for Directors and Senior Management

Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. announces its remuneration plan for directors and senior management. The plan aims to standardize management, incentivize performance, and promote sustainable development. It outlines remuneration standards for independent directors, non-independent directors, and senior management, including basic salary, performance-based pay, and long-term incentives, effective upon shareholder approval.

Management System for Remuneration of Directors and Senior Management

This document outlines the management system for the remuneration of directors and senior management of Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. It details the principles, management bodies, standards, and adjustment mechanisms for remuneration, aiming to incentivize performance and ensure alignment with company strategy and development. The system covers basic salary, performance-based pay, long-term incentives, and other allowances.

Announcement on the Appointment of the Secretary of the Board of Directors

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. announces the appointment of Mr. Li Zejun as the Secretary of the Board of Directors, effective from the date of the board meeting until the end of the sixth board's term. Mr. Li possesses the required qualifications and experience. This appointment signifies that Mr. Chen Pei will no longer act as the interim Secretary of the Board.

Notice of the 2026 Third Extraordinary Shareholders' Meeting

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. announces its 2026 Third Extraordinary Shareholders' Meeting on May 28, 2026. The meeting will discuss proposals including amendments to the remuneration system for directors and senior management. Shareholders can vote in person or via online platforms.

Announcement on the Resolutions of the 26th Meeting of the 6th Board of Directors

This announcement details the resolutions passed at the 26th meeting of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd.'s 6th Board of Directors. Key decisions included revising the remuneration management system for directors and senior management, approving the remuneration plan, and appointing a new Board Secretary. These resolutions are subject to shareholder approval.

Announcement on Participating in the 2026 Guizhou Regulatory Area Listed Companies Investor Collective Reception Day and 2025 Annual Performance Briefing

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. will participate in the 2026 Guizhou Regulatory Area Listed Companies Investor Collective Reception Day and 2025 Annual Performance Briefing. The event aims to enhance communication with investors and provide insights into the company's 2025 performance. The briefing will be held online on May 11, 2026, with a Q&A session for investors.

Legal Opinion on the Second Extraordinary General Meeting of 2026

This legal opinion reviews the convening and holding of Guizhou Big Dipper Pharmaceutical Co., Ltd.'s Second Extraordinary General Meeting in 2026. It confirms the procedures, attendee qualifications, and voting processes complied with relevant laws and regulations. However, both proposals discussed at the meeting failed to pass due to insufficient votes.

Announcement on the Resolution of the Second Extraordinary Shareholders' Meeting in 2026

This announcement details the resolutions of Guizhou BaiLing Pharmaceutical Co., Ltd.'s second extraordinary shareholders' meeting in 2026. The meeting discussed and voted on proposals to amend the Articles of Association and the Rules of Procedure for the Board of Directors. Both proposals failed to pass, with a significant number of votes against them. The meeting was convened and conducted in compliance with relevant laws and regulations.

2019-2021 Annual Audit Report

Assurance Report on the Correction of Significant Prior Period Errors

This report provides assurance on the management's explanation regarding the correction of significant prior period errors by Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. The report confirms that the explanation complies with accounting standards and reflects the correction of errors affecting the 2024 financial statements. The adjustments primarily impact retained earnings and undistributed profits.

2023 Annual Audit Report

Guizhou BaiLing Enterprise Group Pharmaceutical Co., Ltd. 2019-2021 Annual Financial Report

This report presents the consolidated and parent company financial statements for Guizhou BaiLing Enterprise Group Pharmaceutical Co., Ltd. from 2019 to 2021. Key figures include total assets, liabilities, and owner's equity, with detailed breakdowns for operating, investing, and financing activities. The company's financial performance and position over the three-year period are presented.

Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. 2023 Annual Financial Report

Announcement on Correction of Prior Accounting Errors and Retrospective Adjustment

Guizhou BaiLing Pharmaceutical Co., Ltd. announces the correction of prior accounting errors and retrospective adjustment. This correction impacts the net profit for 2019 and 2020, turning them from profit to loss. The company received an administrative penalty for false reporting in its annual reports. The adjustments are made in accordance with accounting standards and disclosure rules.

Announcement on the Proposed Re-appointment of 2026 Financial and Internal Control Audit Institutions

Guizhou BaiLing Pharmaceutical Group Co., Ltd. proposes to re-appoint Tianjian Certified Public Accountants (Special General Partnership) as its financial and internal control audit institution for 2026. This decision follows the Audit Committee's review and the Board of Directors' approval. The proposal will be submitted to the shareholders' meeting for final approval.

2025 Annual Independent Director's Report (Hu Jian)

This report details the performance of Independent Director Hu Jian for 2025. It covers his basic information, attendance at board and shareholder meetings, participation in special committees, and communication with stakeholders. The report also addresses regulatory actions taken against the company and the director's reflections and future commitments.

2025 Annual Independent Director's Performance Report (Yan Guowen)

This report details the performance of Independent Director Yan Guowen for 2025. It covers attendance at board and shareholder meetings, participation in special committees, and the exercise of special director rights. The director focused on corporate governance, financial reporting, and protecting shareholder interests, particularly those of small and medium shareholders. The report concludes with an overall evaluation and recommendations for 2026.

2025 Annual Report of Independent Director (Yang Ming)

This report details Independent Director Yang Ming's fulfillment of duties in 2025. He attended all required meetings, actively participated in discussions, and exercised independent judgment to protect shareholder interests. Yang Ming focused on regular reporting, auditor re-appointment, accounting error correction, and director/senior management compensation, ensuring compliance and fairness. He will continue to diligently perform his duties in 2026.

2025 Annual Report of Independent Director (Zhang Hongwu)

2025 Internal Control Audit Report

This report presents the internal control audit for Guizhou Bailin Enterprise Group Pharmaceutical Co., Ltd. for the year ending December 31, 2025. The auditors conclude that the company maintained effective internal financial reporting controls in all material respects. The report outlines the responsibilities of both the company and the auditors, and acknowledges the inherent limitations of internal control systems.

2025 Annual Internal Control Self-Evaluation Report

Special Report on the Annual Deposit, Management, and Use of Raised Funds

This report details the annual status of raised funds for Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. It covers the total amount raised, its management through special accounts, and its utilization in various investment projects. The company confirms no significant issues in fund usage or disclosure for the period, with all raised funds accounted for.

Announcement on Convening the 2025 Annual Shareholders' Meeting

Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. announces its 2025 Annual Shareholders' Meeting. The meeting will be held on May 18, 2026, combining in-person and online voting. Shareholders as of May 11, 2026, are eligible to attend. Key agenda items include the Board of Directors' work report, annual report, auditor appointment, profit distribution, and executive compensation.

2025 Annual Board of Directors Work Report

This report details the 2025 work of Guizhou Bai Ling Pharmaceutical Group Co., Ltd.'s Board of Directors. The board adhered to laws and regulations, fulfilled duties, and promoted business development. Key activities included board meetings, committee work, and investor relations. Despite revenue decline, the company focused on strategic platform development and innovation.

Special Explanation by Independent Directors on Matters Related to the 2025 Annual Audit Report's Qualified Opinion

Announcement on the Resolutions of the 25th Meeting of the 6th Board of Directors

This announcement details the resolutions passed at the 25th meeting of the 6th Board of Directors of Guizhou Bai Ling Enterprise Group Pharmaceutical Co., Ltd. Key decisions included approving the 2025 annual reports, the 2025 profit distribution plan, and the reappointment of auditors. The meeting confirmed the company's compliance with relevant laws and regulations.

Announcement on the 2025 Profit Distribution Plan

Guizhou Bai Ling Pharmaceutical Group Co., Ltd. announces its 2025 profit distribution plan. The company will not distribute cash dividends, issue bonus shares, or convert capital reserves into share capital. This decision is due to a negative net profit attributable to shareholders in 2025 and the need to retain funds for development. The plan is subject to shareholder approval.